# A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

> **NCT06672055** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vaxart** · enrollment: 10400 (estimated)

## Conditions studied

- SARS-CoV2
- COVID-19

## Interventions

- **BIOLOGICAL:** VXA-CoV2-3.1
- **BIOLOGICAL:** COMIRNATY®
- **BIOLOGICAL:** VXA-CoV2-3.3

## Key facts

- **NCT ID:** NCT06672055
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 10400 (ESTIMATED)
- **Last updated:** 2025-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672055, "A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06672055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*